Skip to main content

Recipharm AB (publ) Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RCPHF News and Ratings via Email

Sign-up to receive the latest news and ratings for Recipharm AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

About Recipharm AB (publ)

Recipharm AB (publ) provides contract development and manufacturing solutions to the pharmaceutical industry in Sweden, Italy, France, India, Spain, Portugal, Germany, and internationally. It operates through three segments: Manufacturing Steriles & Inhalation, Manufacturing Solids and Others, and Development and Technology. The company manufactures liquid vials and ampoules, lyophilisates, and blow-fill-seal products and inhalation; and tablets, capsules, semi-solids, and non-sterile liquids on behalf of pharmaceutical companies. It also provides supplementary services, such as regulatory, supply chain, active life cycle management, and stability studies and analytical method development services, as well as gateway release and testing services. In addition, the company offers pharmaceutical development services based on various technologies, such as drug substance, drug product, and clinical services to pharmaceutical companies in the drug development phase for new pharmaceuticals; and access to a range of proprietary technologies and intellectual property. Further, it supplies medical devices and veterinary products; and solid, semi-solid, liquid, injectable, and ophthalmic products, as well as serialization services. The company serves various pharma, and research and development companies. The company was founded in 1995 and is headquartered in Stockholm, Sweden.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Industry Biotechnology
Phone46 86 02 52 00
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.00 out of 5 stars

Medical Sector

1077th out of 2,039 stocks

Biotechnology Industry

57th out of 157 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Recipharm AB (publ) (OTCMKTS:RCPHF) Frequently Asked Questions

Is Recipharm AB (publ) a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recipharm AB (publ) in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Recipharm AB (publ) stock.
View analyst ratings for Recipharm AB (publ)
or view top-rated stocks.

What stocks does MarketBeat like better than Recipharm AB (publ)?

Wall Street analysts have given Recipharm AB (publ) a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Recipharm AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Recipharm AB (publ)'s key executives?

Recipharm AB (publ)'s management team includes the following people:
  • Mr. Thomas Eldered, CEO, Pres & Director (Age 60)
  • Mr. Tobias Hägglöv, Chief Financial Officer (Age 42)
  • Mr. Mark Quick, Exec. VP of Corp. Devel. (Age 54)
  • Mr. Jonas Lejontand, VP of HR (Age 42)
  • Mr. Thomas Beck, Sr. VP of Quality Management (Age 51)
  • Mr. Jean-François Hilaire, Exec. VP of Strategy & Global Integration (Age 56)
  • Mr. Bernard Pluta, Pres of Devel. Services (Age 56)
  • Mr. Erik Haeffler, VP of Manufacturing Services & Head of Sustainability (Age 53)
  • Mr. Anders Högdin Ph.D., Head of Bus. Devel. & Sales Team - Europe
  • Mr. Kjell Johansson, Pres of Manufacturing Services - Europe (Age 64)

Who are some of Recipharm AB (publ)'s key competitors?

What is Recipharm AB (publ)'s stock symbol?

Recipharm AB (publ) trades on the OTCMKTS under the ticker symbol "RCPHF."

How do I buy shares of Recipharm AB (publ)?

Shares of RCPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recipharm AB (publ)'s stock price today?

One share of RCPHF stock can currently be purchased for approximately $16.05.

How many employees does Recipharm AB (publ) have?

Recipharm AB (publ) employs 7,383 workers across the globe.

What is Recipharm AB (publ)'s official website?

The official website for Recipharm AB (publ) is

How can I contact Recipharm AB (publ)?

The company can be reached via phone at 46 86 02 52 00.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.